Structure Therapeutics (GPCR) News Today $23.70 +0.31 (+1.30%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$24.10 +0.41 (+1.71%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low - Here's What HappenedStructure Therapeutics (NASDAQ:GPCR) Sets New 1-Year Low - What's Next?February 19 at 2:34 AM | marketbeat.comShort Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Declines By 20.4%Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 7,850,000 shares, a decline of 20.4% from the January 15th total of 9,860,000 shares. Based on an average trading volume of 885,400 shares, the short-interest ratio is presently 8.9 days. Approximately 14.5% of the company's stock are short sold.February 16, 2025 | marketbeat.comWhy Structure Therapeutics Stock Was Stumbling This WeekFebruary 14, 2025 | fool.comabrdn plc Has $4.65 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)abrdn plc decreased its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 21.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 171,388 shares of the company's stock after selling 45,695 shares during the quaFebruary 10, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.7% - Should You Sell?Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.7% - What's Next?February 7, 2025 | marketbeat.com8,949 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Spire Wealth ManagementSpire Wealth Management purchased a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,949 shares of the company's stoFebruary 7, 2025 | marketbeat.comSA Asks: What's the most attractive weight-loss stock right now?February 5, 2025 | msn.comStructure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Rating of "Buy" by BrokeragesStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price target among brFebruary 3, 2025 | marketbeat.comCCG Wealth Management LLC Takes Position in Structure Therapeutics Inc. (NASDAQ:GPCR)CCG Wealth Management LLC acquired a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 150,000 shares of the company's stock, valuedFebruary 3, 2025 | marketbeat.comShort Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8%Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 10,750,000 shares, an increase of 5.8% from the December 31st total of 10,160,000 shares. Currently, 19.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 824,600 shares, the days-to-cover ratio is currently 13.0 days.February 3, 2025 | marketbeat.comStructure Therapeutics to Participate in Multiple Upcoming Healthcare Investor ConferencesJanuary 30, 2025 | globenewswire.comStructure Therapeutics (NASDAQ:GPCR) Trading 8.3% Higher - Should You Buy?Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 8.3% - Time to Buy?January 29, 2025 | marketbeat.comWe're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn RateJanuary 24, 2025 | finance.yahoo.comJPMorgan Chase & Co. Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR)JPMorgan Chase & Co. raised its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 302.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,936 shares of the company's stock afterJanuary 24, 2025 | marketbeat.comExicure Buys GPCR USA From GPCR Therapeutics, Signs L&C Deal; Stock ClimbsJanuary 23, 2025 | markets.businessinsider.comStructure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low - Should You Sell?Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low - What's Next?January 10, 2025 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Receives Consensus Rating of "Buy" from AnalystsStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has been assigned an average rating of "Buy" from the eight analysts that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 1-year target price amongJanuary 9, 2025 | marketbeat.comStifel Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy RecommendationJanuary 8, 2025 | msn.comStructure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - What's Next?January 8, 2025 | marketbeat.comStifel Nicolaus Initiates Coverage on Structure Therapeutics (NASDAQ:GPCR)Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday. They set a "buy" rating and a $50.00 price target for the company.January 8, 2025 | marketbeat.comInnovative Oral Treatments for Obesity: Structure Therapeutics Earns Buy Rating with Promising Pipeline and Strategic VisionJanuary 8, 2025 | markets.businessinsider.comStructure Therapeutics initiated with a Buy at StifelJanuary 8, 2025 | markets.businessinsider.comStructure Therapeutics: Competitive Data Is EmergingJanuary 3, 2025 | seekingalpha.comStructure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year Low - Here's WhyStructure Therapeutics (NASDAQ:GPCR) Hits New 1-Year Low - What's Next?December 31, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5% - Here's WhyStructure Therapeutics (NASDAQ:GPCR) Trading Down 5.5% - Here's What HappenedDecember 30, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Trading 5.6% Higher - Still a Buy?Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.6% - What's Next?December 26, 2024 | marketbeat.comPrincipal Financial Group Inc. Has $23.94 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Principal Financial Group Inc. increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 230.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 545,December 26, 2024 | marketbeat.comBarclays PLC Buys 31,815 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Barclays PLC increased its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 64.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,138 shares of the company's stock after pDecember 23, 2024 | marketbeat.comBuy Rating for Structure Therapeutics, Inc. Driven by Innovative Drug Development and Promising Obesity Treatment PlatformDecember 20, 2024 | markets.businessinsider.comStructure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Here's WhyStructure Therapeutics (NASDAQ:GPCR) Shares Gap Up - What's Next?December 20, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Trading Up 6.6% - What's Next?Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.6% - Still a Buy?December 19, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday.December 19, 2024 | marketbeat.comStructure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Piper SandlerDecember 19, 2024 | markets.businessinsider.comFranklin Resources Inc. Buys 60,397 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Franklin Resources Inc. increased its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 9.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 706,106 shares of the company's stock after purchDecember 19, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Sets New 1-Year Low - Here's WhyStructure Therapeutics (NASDAQ:GPCR) Sets New 1-Year Low - Here's What HappenedDecember 18, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Given Market Outperform Rating at JMP SecuritiesJMP Securities reiterated a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday.December 18, 2024 | marketbeat.comStructure Therapeutics Advances Obesity Treatment CandidateDecember 17, 2024 | markets.businessinsider.comStructure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityDecember 17, 2024 | globenewswire.comStructure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Down 6.1% in NovemberStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 10,550,000 shares, a decrease of 6.1% from the November 15th total of 11,230,000 shares. Approximately 19.5% of the company's stock are short sold. Based on an average daily trading volume, of 788,200 shares, the short-interest ratio is presently 13.4 days.December 17, 2024 | marketbeat.comIs Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds?December 16, 2024 | insidermonkey.comStructure Therapeutics Inc. (NASDAQ:GPCR) Given Average Rating of "Buy" by BrokeragesStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has earned a consensus recommendation of "Buy" from the seven research firms that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month prDecember 15, 2024 | marketbeat.comExome Asset Management LLC Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)Exome Asset Management LLC acquired a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 120,165 shares of the company's stock, valuedDecember 14, 2024 | marketbeat.comY Intercept Hong Kong Ltd Makes New $1.79 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)Y Intercept Hong Kong Ltd purchased a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 40,706 shares of the company's stock, valuedDecember 11, 2024 | marketbeat.comPier Capital LLC Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Pier Capital LLC raised its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 32.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,291 shares of the company's stock after acquDecember 8, 2024 | marketbeat.comWellington Management Group LLP Purchases 221,851 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Wellington Management Group LLP lifted its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 2.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,769,771 shares of the company's stock after purchasing an additional 221,851 shares dDecember 8, 2024 | marketbeat.comOptimistic Outlook on Structure Therapeutics: Promising Drug Development Progress and Future MilestonesDecember 6, 2024 | markets.businessinsider.comStructure Therapeutics (NASDAQ:GPCR) Shares Gap Up - What's Next?Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Still a Buy?December 6, 2024 | marketbeat.comFY2024 Earnings Estimate for GPCR Issued By HC WainwrightStructure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued to clients and investors on Wednesday, December 4th. HC Wainwright analyst A. Ghosh expects that the company will pDecember 6, 2024 | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for GPCR EarningsStructure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Leerink Partnrs decreased their FY2024 earnings per share estimates for Structure Therapeutics in a report released on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share oDecember 6, 2024 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Holdings Boosted by Bank of Montreal CanBank of Montreal Can grew its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 71.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,502 shares of the company's stock after pDecember 6, 2024 | marketbeat.com Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address GPCR Media Mentions By Week GPCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GPCR News Sentiment▼-0.030.60▲Average Medical News Sentiment GPCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GPCR Articles This Week▼24▲GPCR Articles Average Week Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Elanco Animal Health News Lantheus News Nuvalent News Cytokinetics News Verona Pharma News Grifols News TG Therapeutics News Krystal Biotech News SpringWorks Therapeutics News Biohaven News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GPCR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts